News

Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.

  • Rising Demand Driving CBD Market Growth

    July 29, 2022
    In 2021, the global CBD market was valued at $4.20B. The market is projected to reach US$12.64 billion by 2026, according to a report by Research & Markets. Growing regulatory approvals is a major driver of the market. The CBD market is expected to grow at a CAGR of 25.53% during the forecast period of 2022-2026. read more
  • Excipients Market Players Focus on Delivery to Fuel Growth

    August 01, 2022
    The global pharmaceutical excipients market is estimated to register growth at a CAGR of 5% during the forecast period 2019 - 2027, according to an assessment by Transparency Market Research (TMR). read more
  • Aging Population Driving Global Compounding Market

    August 01, 2022
    The global compounding pharmacy market size is estimated to be USD 9.2 billion and is expected to witness a CAGR of 9.45% to 2029. read more
  • Multiple Drivers Propelling CF Treatments

    August 02, 2022
    The global market for cystic fibrosis therapeutics is projected to grow at a compound annual growth rate (CAGR) of 10% during the forecast period of 2022 to 2030, according to a report from Research & Markets. read more
  • Phase 3 Trial of Metastatic Prostate Cancer Treatment Enrollment Completed

    August 02, 2022
    Tavanta Therapeutics, a pharmaceutical company announced the completion of patient enrollment in the company's l Phase 3 study for TAVT-45 (abiraterone acetate) Granules for Oral Suspension ("TAVT-45"). TAVT45CO2 is a global Phase 3 clinical trial evaluating TAVT-45 in patients with metastatic castrate-sensitive prostate cancer (mCSPC) and ... read more
  • Ascletis Cleared for Phase Ib in Mild-to-Moderate COVID-19 Patients

    August 03, 2022
    Ascletis Pharma announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ASC10, an oral drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19, to conduct the Phase Ib clinical trial in mild-to-moderate COVID-19 patients. read more
  • Global Softgel Capsules Market Size Worth $14.3 billion by 2030

    August 03, 2022
    The global softgel capsules market is expected to reach$ 14.3B by 2030 owing to the rising prevalence of chronic diseases and increased R&D investments by the key players, according to Growth Plus Reports. read more
  • Steady Growth Forecasted for Indian Generics Market

    August 04, 2022
    The Indian Generic Drugs Market stood at $24.53B in 2022 and is expected to grow at a steady CAGR of 6.97% during the forecast period. read more
  • Chronic Diseases Driving Mid-Size Pharma Market

    August 08, 2022
    The mid-size pharmaceutical market is expected to grow from$6,51,349.9 million in 2021 to $10,00,584.3 million by 2028. read more
  • Oral Biologics Company Obtains Funding

    August 08, 2022
    Rani Therapeutics Holdings, a company focused on the oral delivery of biologics, announced that it has entered into a loan agreement with Avenue Venture Opportunities Fund for up to $45M of funding. read more
  • JAMP Pharma Corporation Recalls Atorvastatin Tablets

    August 09, 2022
    JAMP Pharma Corporation is voluntarily, on a precautionary basis, recalling one product lot of Atorvastatin tablets, 40 mg, 500-format (lot MHC1403A) to the retail level (type 1 recall). read more
  • New Epilepsy Drug Application Filed in Canada and Israel

    August 09, 2022
    SK Biopharmaceuticals announced that Health Canada has accepted Paladin Labs Inc.'s filing of a New Drug Submission (NDS) for cenobamate as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. read more
  • FDA Approves Lymphoma Tablet

    August 09, 2022
    AstraZeneca’s new tablet formulation of CALQUENCE® (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under accelerated approval based on ... read more
  • Catalent to Acquire Metrics Contract Services for $475M

    August 10, 2022
    Catalent announced that it has reached an agreement to acquire Metrics Contract Services, a full-service specialty contract development and manufacturing organization (CDMO) with a facility in Greenville, North Carolina, for $475M from Mayne Pharma Group Limited. read more
  • Generics, Chronic Diseases Driving Prescription Drug Growth

    August 11, 2022
    The increased number of generic versions of several key medications being launched in strong areas such as the United States is driving the global prescription drugs market, according to a report by Data Bridge Market Research. Its market analysis says the global market was valued at $1,015.63B in 2021 and is expected to reach $1,482.35B by 2029, ... read more